Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Merck & Co. has signed clinical research pacts with three rival companies to evaluate combinations of their drugs with MK-3475, a Merck antibody in development as a cancer immunotherapy. Merck will study MK-3475 in combination with Pfizer’s small-molecule kinase inhibitor Inlyta. The firm will investigate a combination of MK-3475 with Incyte’s investigational immunotherapy INCB24360. And Merck will test its drug with talimogene laherparepvec, an Amgen drug now in development. FDA dubbed MK-3475 a breakthrough therapy last year.
This article has been sent to the following recipient: